Trial Profile

A Randomized, Single-Center, Open-Label, Single-dose, 4-Period, 2-Sequence, Fully Replicate Crossover Study To Assess The Bioequivalence Of A Test Fixed Dose Combination Product Versus The Co-Administered Individual Reference Products Containing Bempedoic Acid 180 mg, Ezetimibe 10 mg And Rosuvastatin 20 mg In Healthy Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bempedoic acid/ezetimibe/rosuvastatin (Primary) ; Bempedoic acid; Ezetimibe; Rosuvastatin
Indications Dyslipidaemias
Focus Pharmacokinetics
Sponsors Daiichi Sankyo Company

18 Nov 2025 Status changed from not yet recruiting to recruiting.
29 Sep 2025 Planned End Date changed from 25 Nov 2025 to 18 Nov 2025.
29 Sep 2025 Planned primary completion date changed from 25 Nov 2025 to 18 Nov 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com